Functional stability of plasminogen activator inhibitor-1
about
Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumoniaEnhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions.The Comparison of Adipose Stem Cell and Placental Stem Cell in Secretion Characteristics and in Facial Antiaging.Hyperglycaemia-induced reciprocal changes in miR-30c and PAI-1 expression in platelets.Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases.Is plasminogen activator inhibitor-1 a physiological bottleneck bridging major depressive disorder and cardiovascular disease?The Role of Hemostatic Factors in Atherosclerosis in Patients with Chronic Renal Disease.Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulenceVehicle-dependent Effects of Sphingosine 1-phosphate on Plasminogen Activator Inhibitor-1 Expression.Inhibition of PAI-1 Activity by Toddalolactone as a Mechanism for Promoting Blood Circulation and Removing Stasis by Chinese Herb Zanthoxylum nitidum var. tomentosumMechanism of the protective effects of the combined treatment with rhynchophylla total alkaloids and sinapine thiocyanate against a prothrombotic state caused by vascular endothelial cell inflammatory damageGetting Old through the Blood: Circulating Molecules in Aging and Senescence of Cardiovascular Regenerative Cells.miR-30c may serve a role in endometriosis by targeting plasminogen activator inhibitor-1.Bioactivity-Guided Fractionation of the Traditional Chinese Medicine Resina Draconis Reveals Loureirin B as a PAI-1 Inhibitor.Comprehensive analysis of haemostatic profile depending on clinicopathological determinants in breast cancer patients.
P2860
Q26753030-2814CEE9-61AD-4BA6-AE25-2155C2430B6DQ36276804-745632E4-594A-4156-9E4E-36929E27E4FDQ36601539-9E9C784D-EEA5-47AF-9396-BFE2ACB356A1Q37397301-6AD31D0E-372C-41F1-A95D-00FEAFEF354DQ38649391-664FBAF3-CB34-4DAC-AD36-3454028C00DFQ38849673-9C4ADD41-613A-41B9-A173-6E09540869A3Q38956831-97E3411D-7439-4D09-ABB2-226639557724Q39633118-59308F28-4FB8-44A8-8AA9-C06EBD5D6ABCQ40287159-15E63455-97A5-49BC-8743-B8D32E08D41AQ41074738-F507AD99-FF46-4EE1-A421-EE1EDF2C61C2Q42235431-3E5B256D-881A-48B5-AC1A-43F24B8343E8Q43192139-C14F3EDF-AF6C-4DB9-8E0A-B2265A778680Q47140132-65FA3869-99EB-40E9-8B76-0F04EE123503Q47168284-F3029518-C07A-4235-8943-8F22B66D1DE7Q54939232-3ACBF38E-8A1C-480D-9757-6F47FC34709C
P2860
Functional stability of plasminogen activator inhibitor-1
description
im Oktober 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 15 October 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2014
@uk
name
Functional stability of plasminogen activator inhibitor-1
@en
Functional stability of plasminogen activator inhibitor-1
@nl
type
label
Functional stability of plasminogen activator inhibitor-1
@en
Functional stability of plasminogen activator inhibitor-1
@nl
prefLabel
Functional stability of plasminogen activator inhibitor-1
@en
Functional stability of plasminogen activator inhibitor-1
@nl
P2860
P921
P356
P1476
Functional stability of plasminogen activator inhibitor-1
@en
P2093
Mehmet Agirbasli
Pinar Kuru
P2860
P304
P356
10.1155/2014/858293
P407
P5008
P577
2014-10-15T00:00:00Z